AVALIAÇÃO DO PLAQUETOGRAMA EM PACIENTES COM TROMBOCITOPENIA IMUNE PRIMÁRIA E PACIENTES COM MIELOSSUPRESSÃO EM UM HOSPITAL DO SUL DO BRASIL Article Swipe
Fernando Nascimento
,
KN Pereira
,
ISO Tioda
,
CF Dutra
,
LB Pasqualoto
,
NC Hoppe
,
ACM Ciceri
,
LE Oliveira
,
C Paniz
,
JAM Carvalho
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.htct.2024.09.920
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.htct.2024.09.920
Objetivo: A Trombocitopenia Imune Primária (PTI) é uma doença autoimune caracterizada pela destruição imunomediada das plaquetas no sangue periférico e por valores de plaquetas abaixo de 100×103/mm3. Já a mielossupressão é uma reação que leva a uma atividade prejudicada dos precursores das células sanguíneas, reduzindo leucócitos, plaquetas e hemoglobina no sangue periférico, podendo apresentar diversos agentes causais. O objetivo do estudo foi analisar diferenças entre o plaquetograma de pacientes com PTI e os com Mielossupressão (PCM). Métodos: Realizou-se um estudo transversal em pacientes adultos com PTI e com PCM atendidos no Hospital Universitário de Santa Maria, entre 2020 e 2023. As análises foram feitas com amostras de sangue total coletadas com EDTA. Os hemogramas foram realizados no analisador XN1000 (Sysmex®). A Fração de Plaquetas Imaturas (IPF), o percentual de plaquetas grandes (P-LCR) e a distribuição do tamanho das plaquetas (PDW) foram realizados pela metodologia de citometria de fluxo e fluorescência. A análise da contagem de plaquetas e do volume plaquetário médio foi realizada por impedância com foco hidrodinâmico. Resultados: Foram incluídos 66 pacientes com PTI e 26 com PCM, diagnosticados com base no histórico médico e exame clínico. A idade média foi de 47 ± 20 anos e 45 (68,2%) eram mulheres no grupo PTI, enquanto para o grupo PCM, foi de 39 ± 20 anos, sendo 6 (23,1%) mulheres (p = 0,106). A mediana da contagem de plaquetas do grupo PTI foi de 62 (42‒83) ×103/mm3 e no grupo PCM 25 (16‒47) ×103/mm3 (p < 0,001). O IPF foi de 13,7 (7,5‒21,3) % no grupo PTI e 8,2 (4,2‒10,3) no grupo PCM (p < 0,001). O percentual de plaquetas grandes (P-LCR) foi de 40,6 (30,7–45,8) % para o grupo PTI e de 26,3 (18,1–32,1) para o grupo PCM (p < 0,001). O Plaquetócrito (PCT) do grupo PTI foi 0,100 (0,070–0,160) % e no grupo PCM de foi de 0,020 (0,017–0,055) % (p < 0,001). A PDW foi de 14,9 (13,0–17,2) fL para PTI e 11,20 (9,9–13,8) fL para PCM (p < 0,001). O VPM para o grupo PTI foi de 14,9 (13,0–17,2) % e no grupo PCM foi de 11,2 (9,9–13,8) (p < 0,001). Discussão: A avaliação do mielograma é o padrão ouro para o diagnóstico de pacientes com PTI, porém índices plaquetários, especialmente o IPF, têm importância significativa atuando como ferramenta diagnóstica útil nas trombocitopenias. Novos parâmetros plaquetários vêm tendo aplicação como auxiliares no diagnóstico de trombocitopenias e, corroboraram no desenvolvimento do plaquetograma, que possibilita criar um perfil para avaliação morfológica e quantificação das plaquetas, na análise do hemograma. Nesse estudo avaliamos o plaquetograma em doenças com fisiopatologias diferentes: a PTI que está relacionada à destruição mediada por anticorpos; e a mielossupressão, a qual é caracterizada por uma medula óssea hipoproliferativa. Quando analisamos os resultados obtidos verificamos um perfil diferente entre o grupo dos pacientes PTI e PCM. Conclusão: Os pacientes com PTI apresentaram maiores valores para IPF, PCT, P-LCR, PDW e VPM em relação aos pacientes PCM, o que demonstra que esses parâmetros podem ser utilizados na clínica para avaliação destes grupos de pacientes. Ressalta-se que estes índices plaquetários são ferramentas de baixo custo permitindo monitorar o perfil plaquetário dos pacientes em diferentes situações.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- pt
- Landing Page
- https://doi.org/10.1016/j.htct.2024.09.920
- OA Status
- diamond
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4403568484
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4403568484Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.htct.2024.09.920Digital Object Identifier
- Title
-
AVALIAÇÃO DO PLAQUETOGRAMA EM PACIENTES COM TROMBOCITOPENIA IMUNE PRIMÁRIA E PACIENTES COM MIELOSSUPRESSÃO EM UM HOSPITAL DO SUL DO BRASILWork title
- Type
-
articleOpenAlex work type
- Language
-
ptPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-10-01Full publication date if available
- Authors
-
Fernando Nascimento, KN Pereira, ISO Tioda, CF Dutra, LB Pasqualoto, NC Hoppe, ACM Ciceri, LE Oliveira, C Paniz, JAM CarvalhoList of authors in order
- Landing page
-
https://doi.org/10.1016/j.htct.2024.09.920Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.htct.2024.09.920Direct OA link when available
- Concepts
-
Medicine, GynecologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4403568484 |
|---|---|
| doi | https://doi.org/10.1016/j.htct.2024.09.920 |
| ids.doi | https://doi.org/10.1016/j.htct.2024.09.920 |
| ids.openalex | https://openalex.org/W4403568484 |
| fwci | 0.0 |
| type | article |
| title | AVALIAÇÃO DO PLAQUETOGRAMA EM PACIENTES COM TROMBOCITOPENIA IMUNE PRIMÁRIA E PACIENTES COM MIELOSSUPRESSÃO EM UM HOSPITAL DO SUL DO BRASIL |
| biblio.issue | |
| biblio.volume | 46 |
| biblio.last_page | S549 |
| biblio.first_page | S549 |
| topics[0].id | https://openalex.org/T13915 |
| topics[0].field.id | https://openalex.org/fields/33 |
| topics[0].field.display_name | Social Sciences |
| topics[0].score | 0.8946999907493591 |
| topics[0].domain.id | https://openalex.org/domains/2 |
| topics[0].domain.display_name | Social Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3312 |
| topics[0].subfield.display_name | Sociology and Political Science |
| topics[0].display_name | Public Health in Brazil |
| topics[1].id | https://openalex.org/T12172 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.8364999890327454 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Neutropenia and Cancer Infections |
| topics[2].id | https://openalex.org/T11314 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.7928000092506409 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2737 |
| topics[2].subfield.display_name | Physiology |
| topics[2].display_name | Clinical Laboratory Practices and Quality Control |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9342890381813049 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C29456083 |
| concepts[1].level | 1 |
| concepts[1].score | 0.622001588344574 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1221899 |
| concepts[1].display_name | Gynecology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9342890381813049 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/gynecology |
| keywords[1].score | 0.622001588344574 |
| keywords[1].display_name | Gynecology |
| language | pt |
| locations[0].id | doi:10.1016/j.htct.2024.09.920 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2898598332 |
| locations[0].source.issn | 2531-1379, 2531-1387 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2531-1379 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Hematology Transfusion and Cell Therapy |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Hematology, Transfusion and Cell Therapy |
| locations[0].landing_page_url | https://doi.org/10.1016/j.htct.2024.09.920 |
| locations[1].id | pmh:oai:doaj.org/article:e93f66e6b5254d199f885db36600fc7e |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].source.host_organization_lineage | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S549- (2024) |
| locations[1].landing_page_url | https://doaj.org/article/e93f66e6b5254d199f885db36600fc7e |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5045286222 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-3568-3887 |
| authorships[0].author.display_name | Fernando Nascimento |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | FG Nascimento |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5043830024 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | KN Pereira |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | KN Pereira |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5107805592 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | ISO Tioda |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | ISO Tioda |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5072634089 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | CF Dutra |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | CF Dutra |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5107805633 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | LB Pasqualoto |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | LB Pasqualoto |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5107805627 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | NC Hoppe |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | NC Hoppe |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5061199192 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | ACM Ciceri |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | ACM Ciceri |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5102245455 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | LE Oliveira |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | LE Oliveira |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5072884896 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | C Paniz |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | C Paniz |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5038532337 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | JAM Carvalho |
| authorships[9].author_position | last |
| authorships[9].raw_author_name | JAM Carvalho |
| authorships[9].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.htct.2024.09.920 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | AVALIAÇÃO DO PLAQUETOGRAMA EM PACIENTES COM TROMBOCITOPENIA IMUNE PRIMÁRIA E PACIENTES COM MIELOSSUPRESSÃO EM UM HOSPITAL DO SUL DO BRASIL |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T13915 |
| primary_topic.field.id | https://openalex.org/fields/33 |
| primary_topic.field.display_name | Social Sciences |
| primary_topic.score | 0.8946999907493591 |
| primary_topic.domain.id | https://openalex.org/domains/2 |
| primary_topic.domain.display_name | Social Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3312 |
| primary_topic.subfield.display_name | Sociology and Political Science |
| primary_topic.display_name | Public Health in Brazil |
| related_works | https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W4389568370, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W1489783725 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1016/j.htct.2024.09.920 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2898598332 |
| best_oa_location.source.issn | 2531-1379, 2531-1387 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2531-1379 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Hematology Transfusion and Cell Therapy |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Hematology, Transfusion and Cell Therapy |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.htct.2024.09.920 |
| primary_location.id | doi:10.1016/j.htct.2024.09.920 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2898598332 |
| primary_location.source.issn | 2531-1379, 2531-1387 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2531-1379 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Hematology Transfusion and Cell Therapy |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Hematology, Transfusion and Cell Therapy |
| primary_location.landing_page_url | https://doi.org/10.1016/j.htct.2024.09.920 |
| publication_date | 2024-10-01 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index.% | 253, 276, 301, 311, 343 |
| abstract_inverted_index.6 | 217 |
| abstract_inverted_index.< | 245, 264, 290, 313, 331, 353 |
| abstract_inverted_index.= | 221 |
| abstract_inverted_index.A | 1, 120, 150, 188, 223, 315, 356 |
| abstract_inverted_index.O | 57, 247, 266, 292, 333 |
| abstract_inverted_index.a | 28, 35, 133, 431, 442, 444 |
| abstract_inverted_index.e | 19, 47, 71, 86, 98, 132, 148, 156, 175, 185, 197, 237, 257, 281, 302, 324, 344, 413, 441, 468, 483 |
| abstract_inverted_index.o | 65, 126, 207, 278, 286, 336, 361, 365, 375, 424, 463, 490, 519 |
| abstract_inverted_index.(p | 220, 244, 263, 289, 312, 330, 352 |
| abstract_inverted_index.20 | 195, 214 |
| abstract_inverted_index.25 | 241 |
| abstract_inverted_index.26 | 176 |
| abstract_inverted_index.39 | 212 |
| abstract_inverted_index.45 | 198 |
| abstract_inverted_index.47 | 193 |
| abstract_inverted_index.62 | 234 |
| abstract_inverted_index.66 | 171 |
| abstract_inverted_index.As | 100 |
| abstract_inverted_index.Os | 112, 471 |
| abstract_inverted_index.da | 152, 225 |
| abstract_inverted_index.de | 22, 25, 67, 93, 106, 122, 128, 144, 146, 154, 192, 211, 227, 233, 250, 268, 273, 282, 306, 308, 318, 340, 349, 367, 397, 505, 514 |
| abstract_inverted_index.do | 59, 135, 157, 229, 295, 358, 403, 419 |
| abstract_inverted_index.e, | 399 |
| abstract_inverted_index.em | 81, 426, 485, 524 |
| abstract_inverted_index.fL | 321, 327 |
| abstract_inverted_index.na | 417, 499 |
| abstract_inverted_index.no | 16, 49, 90, 116, 182, 202, 238, 254, 260, 303, 345, 395, 401 |
| abstract_inverted_index.os | 72, 455 |
| abstract_inverted_index.um | 78, 408, 459 |
| abstract_inverted_index.± | 194, 213 |
| abstract_inverted_index.à | 436 |
| abstract_inverted_index.é | 6, 30, 360, 446 |
| abstract_inverted_index.8,2 | 258 |
| abstract_inverted_index.IPF | 248 |
| abstract_inverted_index.Já | 27 |
| abstract_inverted_index.PCM | 88, 240, 262, 288, 305, 329, 347 |
| abstract_inverted_index.PDW | 316, 482 |
| abstract_inverted_index.PTI | 70, 85, 174, 231, 256, 280, 297, 323, 338, 432, 467, 474 |
| abstract_inverted_index.VPM | 334, 484 |
| abstract_inverted_index.aos | 487 |
| abstract_inverted_index.com | 69, 73, 84, 87, 104, 110, 165, 173, 177, 180, 369, 428, 473 |
| abstract_inverted_index.das | 14, 41, 137, 415 |
| abstract_inverted_index.dos | 39, 465, 522 |
| abstract_inverted_index.foi | 61, 161, 191, 210, 232, 249, 272, 298, 307, 317, 339, 348 |
| abstract_inverted_index.nas | 385 |
| abstract_inverted_index.por | 20, 163, 439, 448 |
| abstract_inverted_index.que | 33, 405, 433, 491, 493, 508 |
| abstract_inverted_index.ser | 497 |
| abstract_inverted_index.uma | 7, 31, 36, 449 |
| abstract_inverted_index.11,2 | 350 |
| abstract_inverted_index.13,7 | 251 |
| abstract_inverted_index.14,9 | 319, 341 |
| abstract_inverted_index.2020 | 97 |
| abstract_inverted_index.26,3 | 283 |
| abstract_inverted_index.40,6 | 274 |
| abstract_inverted_index.IPF, | 376, 479 |
| abstract_inverted_index.PCM, | 178, 209, 489 |
| abstract_inverted_index.PCM. | 469 |
| abstract_inverted_index.PCT, | 480 |
| abstract_inverted_index.PTI, | 204, 370 |
| abstract_inverted_index.anos | 196 |
| abstract_inverted_index.base | 181 |
| abstract_inverted_index.como | 381, 393 |
| abstract_inverted_index.eram | 200 |
| abstract_inverted_index.foco | 166 |
| abstract_inverted_index.leva | 34 |
| abstract_inverted_index.ouro | 363 |
| abstract_inverted_index.para | 206, 277, 285, 322, 328, 335, 364, 410, 478, 501 |
| abstract_inverted_index.pela | 11, 142 |
| abstract_inverted_index.qual | 445 |
| abstract_inverted_index.são | 512 |
| abstract_inverted_index.têm | 377 |
| abstract_inverted_index.vêm | 390 |
| abstract_inverted_index.(PCT) | 294 |
| abstract_inverted_index.(PDW) | 139 |
| abstract_inverted_index.(PTI) | 5 |
| abstract_inverted_index.0,020 | 309 |
| abstract_inverted_index.0,100 | 299 |
| abstract_inverted_index.11,20 | 325 |
| abstract_inverted_index.2023. | 99 |
| abstract_inverted_index.EDTA. | 111 |
| abstract_inverted_index.Foram | 169 |
| abstract_inverted_index.Imune | 3 |
| abstract_inverted_index.Nesse | 421 |
| abstract_inverted_index.Novos | 387 |
| abstract_inverted_index.Santa | 94 |
| abstract_inverted_index.anos, | 215 |
| abstract_inverted_index.baixo | 515 |
| abstract_inverted_index.criar | 407 |
| abstract_inverted_index.custo | 516 |
| abstract_inverted_index.entre | 64, 96, 462 |
| abstract_inverted_index.esses | 494 |
| abstract_inverted_index.estes | 509 |
| abstract_inverted_index.está | 434 |
| abstract_inverted_index.exame | 186 |
| abstract_inverted_index.fluxo | 147 |
| abstract_inverted_index.foram | 102, 114, 140 |
| abstract_inverted_index.grupo | 203, 208, 230, 239, 255, 261, 279, 287, 296, 304, 337, 346, 464 |
| abstract_inverted_index.idade | 189 |
| abstract_inverted_index.podem | 496 |
| abstract_inverted_index.sendo | 216 |
| abstract_inverted_index.tendo | 391 |
| abstract_inverted_index.total | 108 |
| abstract_inverted_index.útil | 384 |
| abstract_inverted_index.(IPF), | 125 |
| abstract_inverted_index.(PCM). | 75 |
| abstract_inverted_index.Maria, | 95 |
| abstract_inverted_index.P-LCR, | 481 |
| abstract_inverted_index.Quando | 453 |
| abstract_inverted_index.XN1000 | 118 |
| abstract_inverted_index.abaixo | 24 |
| abstract_inverted_index.destes | 503 |
| abstract_inverted_index.estudo | 60, 79, 422 |
| abstract_inverted_index.feitas | 103 |
| abstract_inverted_index.grupos | 504 |
| abstract_inverted_index.medula | 450 |
| abstract_inverted_index.média | 190 |
| abstract_inverted_index.médio | 160 |
| abstract_inverted_index.perfil | 409, 460, 520 |
| abstract_inverted_index.porém | 371 |
| abstract_inverted_index.sangue | 17, 50, 107 |
| abstract_inverted_index.volume | 158 |
| abstract_inverted_index.óssea | 451 |
| abstract_inverted_index.(23,1%) | 218 |
| abstract_inverted_index.(68,2%) | 199 |
| abstract_inverted_index.(P-LCR) | 131, 271 |
| abstract_inverted_index.0,001). | 246, 265, 291, 314, 332, 354 |
| abstract_inverted_index.0,106). | 222 |
| abstract_inverted_index.adultos | 83 |
| abstract_inverted_index.agentes | 55 |
| abstract_inverted_index.atuando | 380 |
| abstract_inverted_index.doença | 8 |
| abstract_inverted_index.grandes | 130, 270 |
| abstract_inverted_index.maiores | 476 |
| abstract_inverted_index.mediada | 438 |
| abstract_inverted_index.mediana | 224 |
| abstract_inverted_index.médico | 184 |
| abstract_inverted_index.obtidos | 457 |
| abstract_inverted_index.padrão | 362 |
| abstract_inverted_index.podendo | 52 |
| abstract_inverted_index.tamanho | 136 |
| abstract_inverted_index.valores | 21, 477 |
| abstract_inverted_index.Fração | 121 |
| abstract_inverted_index.Hospital | 91 |
| abstract_inverted_index.Imaturas | 124 |
| abstract_inverted_index.amostras | 105 |
| abstract_inverted_index.analisar | 62 |
| abstract_inverted_index.análise | 151, 418 |
| abstract_inverted_index.causais. | 56 |
| abstract_inverted_index.clínica | 500 |
| abstract_inverted_index.contagem | 153, 226 |
| abstract_inverted_index.células | 42 |
| abstract_inverted_index.diversos | 54 |
| abstract_inverted_index.doenças | 427 |
| abstract_inverted_index.enquanto | 205 |
| abstract_inverted_index.mulheres | 201, 219 |
| abstract_inverted_index.objetivo | 58 |
| abstract_inverted_index.reação | 32 |
| abstract_inverted_index.índices | 372, 510 |
| abstract_inverted_index.(16‒47) | 242 |
| abstract_inverted_index.(42‒83) | 235 |
| abstract_inverted_index.Métodos: | 76 |
| abstract_inverted_index.Objetivo: | 0 |
| abstract_inverted_index.Plaquetas | 123 |
| abstract_inverted_index.Primária | 4 |
| abstract_inverted_index.análises | 101 |
| abstract_inverted_index.atendidos | 89 |
| abstract_inverted_index.atividade | 37 |
| abstract_inverted_index.autoimune | 9 |
| abstract_inverted_index.avaliamos | 423 |
| abstract_inverted_index.clínico. | 187 |
| abstract_inverted_index.coletadas | 109 |
| abstract_inverted_index.demonstra | 492 |
| abstract_inverted_index.diferente | 461 |
| abstract_inverted_index.monitorar | 518 |
| abstract_inverted_index.pacientes | 68, 82, 172, 368, 466, 472, 488, 523 |
| abstract_inverted_index.plaquetas | 15, 23, 46, 129, 138, 155, 228, 269 |
| abstract_inverted_index.realizada | 162 |
| abstract_inverted_index.reduzindo | 44 |
| abstract_inverted_index.relação | 486 |
| abstract_inverted_index.×103/mm3 | 236, 243 |
| abstract_inverted_index.analisador | 117 |
| abstract_inverted_index.analisamos | 454 |
| abstract_inverted_index.apresentar | 53 |
| abstract_inverted_index.auxiliares | 394 |
| abstract_inverted_index.citometria | 145 |
| abstract_inverted_index.diferentes | 525 |
| abstract_inverted_index.ferramenta | 382 |
| abstract_inverted_index.hemograma. | 420 |
| abstract_inverted_index.hemogramas | 113 |
| abstract_inverted_index.histórico | 183 |
| abstract_inverted_index.incluídos | 170 |
| abstract_inverted_index.mielograma | 359 |
| abstract_inverted_index.pacientes. | 506 |
| abstract_inverted_index.percentual | 127, 267 |
| abstract_inverted_index.permitindo | 517 |
| abstract_inverted_index.plaquetas, | 416 |
| abstract_inverted_index.realizados | 115, 141 |
| abstract_inverted_index.resultados | 456 |
| abstract_inverted_index.utilizados | 498 |
| abstract_inverted_index.(Sysmex®). | 119 |
| abstract_inverted_index.Conclusão: | 470 |
| abstract_inverted_index.Discussão: | 355 |
| abstract_inverted_index.Realizou-se | 77 |
| abstract_inverted_index.Ressalta-se | 507 |
| abstract_inverted_index.Resultados: | 168 |
| abstract_inverted_index.anticorpos; | 440 |
| abstract_inverted_index.aplicação | 392 |
| abstract_inverted_index.avaliação | 357, 411, 502 |
| abstract_inverted_index.diferentes: | 430 |
| abstract_inverted_index.diferenças | 63 |
| abstract_inverted_index.ferramentas | 513 |
| abstract_inverted_index.hemoglobina | 48 |
| abstract_inverted_index.impedância | 164 |
| abstract_inverted_index.metodologia | 143 |
| abstract_inverted_index.parâmetros | 388, 495 |
| abstract_inverted_index.periférico | 18 |
| abstract_inverted_index.possibilita | 406 |
| abstract_inverted_index.precursores | 40 |
| abstract_inverted_index.prejudicada | 38 |
| abstract_inverted_index.relacionada | 435 |
| abstract_inverted_index.transversal | 80 |
| abstract_inverted_index.verificamos | 458 |
| abstract_inverted_index.(4,2‒10,3) | 259 |
| abstract_inverted_index.(7,5‒21,3) | 252 |
| abstract_inverted_index.(9,9–13,8) | 326, 351 |
| abstract_inverted_index.apresentaram | 475 |
| abstract_inverted_index.corroboraram | 400 |
| abstract_inverted_index.destruição | 12, 437 |
| abstract_inverted_index.diagnóstica | 383 |
| abstract_inverted_index.diagnóstico | 366, 396 |
| abstract_inverted_index.importância | 378 |
| abstract_inverted_index.imunomediada | 13 |
| abstract_inverted_index.leucócitos, | 45 |
| abstract_inverted_index.morfológica | 412 |
| abstract_inverted_index.periférico, | 51 |
| abstract_inverted_index.plaquetário | 159, 521 |
| abstract_inverted_index.sanguíneas, | 43 |
| abstract_inverted_index.situações. | 526 |
| abstract_inverted_index.(13,0–17,2) | 320, 342 |
| abstract_inverted_index.(18,1–32,1) | 284 |
| abstract_inverted_index.(30,7–45,8) | 275 |
| abstract_inverted_index.100×103/mm3. | 26 |
| abstract_inverted_index.caracterizada | 10, 447 |
| abstract_inverted_index.especialmente | 374 |
| abstract_inverted_index.plaquetograma | 66, 425 |
| abstract_inverted_index.plaquetários | 389, 511 |
| abstract_inverted_index.significativa | 379 |
| abstract_inverted_index.Plaquetócrito | 293 |
| abstract_inverted_index.Universitário | 92 |
| abstract_inverted_index.diagnosticados | 179 |
| abstract_inverted_index.distribuição | 134 |
| abstract_inverted_index.plaquetograma, | 404 |
| abstract_inverted_index.plaquetários, | 373 |
| abstract_inverted_index.(0,017–0,055) | 310 |
| abstract_inverted_index.(0,070–0,160) | 300 |
| abstract_inverted_index.Trombocitopenia | 2 |
| abstract_inverted_index.desenvolvimento | 402 |
| abstract_inverted_index.fisiopatologias | 429 |
| abstract_inverted_index.fluorescência. | 149 |
| abstract_inverted_index.hidrodinâmico. | 167 |
| abstract_inverted_index.quantificação | 414 |
| abstract_inverted_index.Mielossupressão | 74 |
| abstract_inverted_index.mielossupressão | 29 |
| abstract_inverted_index.trombocitopenias | 398 |
| abstract_inverted_index.mielossupressão, | 443 |
| abstract_inverted_index.trombocitopenias. | 386 |
| abstract_inverted_index.hipoproliferativa. | 452 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 10 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.32376012 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |